| |
FDA/HCV-TARGET Collaborate
|
| |
| |
Reported at EASL April 2013, 1st data reported out of TARGET:
HCV-TARGET: A Longitudinal, Observational Study of
North American Patients with Chronic Hepatitis C Treated with Boceprevir or Telaprevir
http://www.natap.org/2013/EASL/EASL_108.htm
FDA, Academia, and Industry Team up to End Hepatitis C
Hepatitis C
http://www.cdcnpin.org
Abstract
A partnership between the US Food and Drug Administration (FDA), the Hepatitis C Therapeutic Registry and Research Network (HCV-TARGET), and the pharmaceutical industry could facilitate better treatment for hepatitis C virus (HCV)-infected people and improve HCV drug development programs. The collaboration will allow the partners to share HCV-TARGET's national data that reveal how hepatitis medications actually are used and managed in routine practice. A goal of this data sharing is providing patients and clinicians with better information about HCV therapies. A project priority is aligning data elements to enable comparison of clinical trial data gathered by FDA and real-world observational data gathered by HCV-TARGET. The collaboration is timely since CDC recently recommended hepatitis C testing for all baby boomers, who account for 75 percent of the estimated 3 million hepatitis C-infected Americans. In addition, the first all-oral HCV drug is in the final stages of FDA approval. As this new medication moves into use, new questions about side effects and drug combinations will emerge. HCV-TARGET includes 103 academic sites and follows approximately 2,500 HCV-infected patients in 31 states, Puerto Rico, Canada, and Europe. Many HCV-TARGET study participants-patients with cirrohosis, African Americans, and patients over age 65-are underrepresented in clinical trials. Since the project's inception in 2011, HCV-TARGET has been studying treatment with boceprevir and telaprivir; observational studies will expand this year to include all antiviral HCV therapies. The University of Florida (UF) is the HCV-TARGET clinical coordinating center, and the University of North Carolina (UNC) is the HCV-TARGET data coordinating center. Co-principal investigators include Dr. David R. Nelson, director of the UF Clinical and Translational Science Institute and a professor of medicine at UF Health, and Dr. Michael W. Fried, professor of medicine at the UNC School of Medicine. HCV-TARGET receives ongoing industry support from Merck, Genentech, Kadmon, and Vertex.
----------------------------------
FDA, academia and industry team up to end hepatitis C
press release from U of Florida
Published: August 29th, 2013
GAINESVILLE, Fla. - As doctors prepare to manage an influx of new hepatitis C patients and treatment options, a collaboration among academia, industry and the U.S. Food and Drug Administration is poised to deliver real-world data that can help doctors and patients optimize their treatment experience.
A research consortium known as the Hepatitis C Therapeutic Registry and Research Network, or HCV-TARGET, has joined forces with the FDA to share national data on how newly approved therapies for hepatitis C are used and managed in routine practice. HCV-TARGET is led jointly by investigators at the University of Florida and the University of North Carolina at Chapel Hill and is sponsored in part by multiple pharmaceutical companies.
HCV-TARGET is rooted in the infrastructure and collaborative network of the national Clinical and Translational Science Award (CTSA) consortium. It is sponsored in part by multiple pharmaceutical companies.
The new partnership's goal is to establish research collaborations using the HCV-TARGET database to better inform patients and clinicians about hepatitis C therapies.
"This collaboration will not only strengthen our ongoing efforts to monitor the safety and effectiveness of existing hepatitis C treatment regimens," said Dr. Janet Woodcock, director of the FDA's Center for Drug Evaluation and Research, "it will also provide opportunities for FDA scientists to apply their research expertise in studying existing data held by HCV-TARGET to identify areas for improvement in clinical trial design that may help improve the future of HCV drug development programs."
Hepatitis C is a viral liver disease that can lead to liver damage, cirrhosis, liver failure or liver cancer. It is transmitted through contact with infected blood. Because a person with chronic hepatitis C can live symptom-free for decades, many people do not know they are infected.
Two factors increase the significance of this collaboration:
¥ More patients to be screened and treated - Within the last year, both the Centers for Disease Control and Prevention and the U.S. Preventive Services Task Force recommended all baby boomers be tested for hepatitis C. The CDC estimates baby boomers represent three-quarters of the more than 3 million Americans believed to be infected with hepatitis C. Among those at highest risk are individuals who received blood transfusions before 1992, when screening donated blood for the virus began.
¥ New treatments on the horizon - The first all-oral hepatitis C treatment is moving through the final stages of FDA approval. If approved, it would be the first of a new generation of hepatitis C drugs that will improve what for many has been a grueling treatment regimen that can take up to 48 weeks and requires injections of interferon, a drug that can be difficult to tolerate. The introduction of new drugs will bring new questions about managing side effects, drug combinations and other clinical considerations.
"Leading liver doctors across the country have joined HCV-TARGET to study and navigate rapidly evolving treatment paradigms for hepatitis C. We see a healthier future for patients battling this virus and formed HCV-TARGET to help guide the way," said Dr. David R. Nelson, co-principal investigator, director of the UF Clinical and Translational Science Institute and a professor of medicine at UF Health, which serves as the clinical coordinating center for HCV-TARGET.
Following close to 2,500 patients in North America who have agreed to participate in its study to date, HCV-TARGET includes populations underrepresented in clinical trials such as patients with cirrhosis, patients age 65 and older and African-Americans. The initial focus of the network's observational study has been treatment with boceprevir and telaprevir, drugs newly approved by the FDA when HCV-TARGET launched in 2011. HCV-TARGET will expand its study this year to include the entire spectrum of antiviral hepatitis C therapeutics.
"Real-world data about how drugs perform outside of restricted clinical trials are extremely important. HCV-TARGET allows us to capture this information using novel approaches to ensure the integrity and quality of the data. Through our partnership with the FDA, we hope this information can be used to help doctors and their patients more readily determine the most beneficial treatment options across a broad spectrum of patients," said Dr. Michael W. Fried, co-principal investigator and professor of medicine at the UNC School of Medicine, which serves as the HCV-TARGET data coordinating center.
HCV-TARGET and the FDA signed in May a memorandum of understanding to promote scientific research in the area of hepatitis C drug development. In mid-July, HCV-TARGET held meetings with representatives from the FDA Center for Drug Evaluation and Research's division of antiviral products and offices of computational science, clinical pharmacology and biostatistics. Attendees agreed one of the first priorities should be to align how data elements of common interest are defined so the clinical trial data collected by the FDA can be reasonably compared to the real-world observational data collected by HCV-TARGET, a critical step in developing research collaborations and pilot projects. In addition, the agreement allows an FDA representative to join HCV-TARGET's advisory council.
HCV-TARGET includes 103 academic and community sites in 31 states, Puerto Rico, Canada and Europe. HCV-TARGET currently receives ongoing industry support from Merck, Genentech, Kadmon and Vertex. Fried receives research grant support from and serves as ad hoc consultant to Genentech, Vertex, Merck, Gilead, Bristol Myers Squibb, Janssen Pharmaceuticals and Abbott. Nelson receives grant support from Genentech, Kadmon, Merck, Vertex, Gilead, Boehringer Ingelheim and Abbott/Abbvie; and payment for the development of educational presentations from Clinical Care Options, Rush University Medical Center, Practice Point Communications and the Chronic Liver Disease Foundation.
HCV-TARGET website
Media Contact
Claire Baralt (UF), cbaralt@ufl.edu, 352-273-8211
Media Contact
Michelle Maclay (UNC), maclay@med.unc.edu, 919-843-5365
|
|
| |
| |
|
|
|
